NR AXOP
AU Holznagel,E.; Yutzy,B.; Deslys,J.P.; Lasmezas,C.; Pocchiari,M.; Ingrosso,L.; Bierke,P.; Schulz-Schaeffer,W.J.; Motzkus,D.; Hunsmann,G.; Löwer,J.
TI Experimental BSE Infection of Non-human Primates: Efficacy of the Oral Route
QU International Conference - Prion 2007 (26.-28.9.2007) Edinburgh International Conference Centre, Edinburgh, Scotland, UK - Book of Abstracts: Epidemiology, Risk Assessment and Transmission P04.27
IA http://www.prion2007.com/pdf/Prion Book of Abstracts.pdf
PT Konferenz-Poster
AB
Background: In 2001, a study was initiated in primates to assess the risk for humans to contract BSE through contaminated food. For this purpose, BSE brain was titrated in cynomolgus monkeys.
Aims: The primary objective is the determination of the minimal infectious dose (MID50) for oral exposure to BSE in a simian model, and, by in doing this, to assess the risk for humans. Secondly, we aimed at examining the course of the disease to identify possible biomarkers.
Methods: Groups with six monkeys each were orally dosed with lowering amounts of BSE brain: 16g, 5g, 0.5g, 0.05g, and 0.005g. In a second titration study, animals were intracerebrally (i.c.) dosed (50, 5, 0.5, 0.05, and 0.005 mg).
Results: In an ongoing study, a considerable number of high-dosed macaques already developed simian vCJD upon oral or intracerebral exposure or are at the onset of the clinical phase. However, there are differences in the clinical course between orally and intracerebrally infected animals that may influence the detection of biomarkers.
Conclusions: Simian vCJD can be easily triggered in cynomolgus monkeys on the oral route using less than 5 g BSE brain homogenate. The difference in the incubation period between 5 g oral and 5 mg i.c. is only 1 year (5 years versus 4 years). However, there are rapid progressors among orally dosed monkeys that develop simian vCJD as fast as intracerebrally inoculated animals.
The work referenced was performed in partial fulfilment of the study "BSE in primates" supported by the EU (QLK1-2002-01096).
AD E. Holznagel, B. Yutzy, J. Löwer, Paul-Ehrlich-Institut, Germany; J.-P. Deslys, C. Lasmézas, Commissariat à l'Energie Atomique, France; M. Pocchiari, L. Ingrosso, Instituto Superiore di Sanità, Italy; P. Bierke, Swedish Institute for Infectious Disease control, Sweden; W. Schulz-Schaeffer, Georg August University, Germany; D. Motzkus, G. Hunsmann, German Primate Center, Germany
SP englisch
PO Schottland